Cargando…
Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria
BACKGROUND AND AIM: Fermented milk can be used to produce antihypertensive peptides. Lactic acid bacteria (LAB) with its proteolytic system hydrolyze milk protein during fermentation to produce several peptides, which include antihypertensive bioactive peptides. This study aimed to investigate the a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Veterinary World
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096298/ https://www.ncbi.nlm.nih.gov/pubmed/32255978 http://dx.doi.org/10.14202/vetworld.2020.345-353 |
_version_ | 1783510775319494656 |
---|---|
author | Rubak, Yuliana Tandi Nuraida, Lilis Iswantini, Dyah Prangdimurti, Endang |
author_facet | Rubak, Yuliana Tandi Nuraida, Lilis Iswantini, Dyah Prangdimurti, Endang |
author_sort | Rubak, Yuliana Tandi |
collection | PubMed |
description | BACKGROUND AND AIM: Fermented milk can be used to produce antihypertensive peptides. Lactic acid bacteria (LAB) with its proteolytic system hydrolyze milk protein during fermentation to produce several peptides, which include antihypertensive bioactive peptides. This study aimed to investigate the ability of indigenous LAB for the production of angiotensin-I-converting enzyme inhibitory (ACE-I) peptides in fermented milk and to characterize the ACEI peptides. MATERIALS AND METHODS: Reconstituted milk (11%) inoculated with ten LAB isolates, and then incubated at 37°C until it reaches pH 4.6. The evaluation was carried out for LAB count, lactic acid concentration, peptide content, and ACE-I activity. The low molecular weight (MW) peptides (<3 kDa) were identified using Nano LC Ultimate 3000 series system Tandem Q Exactive Plus Orbitrap high-resolution mass spectrometry. RESULTS: The result showed that the ten LAB isolates were able to produce ACE-I in fermented milk with the activities in the range of 22.78±2.55-57.36±5.40%. The activity of ACE-I above 50% produced by Lactobacillus delbrueckii BD7, Lactococcus lactis ssp. lactis BD17, and Lactobacillus kefiri YK4 and JK17, with the highest activity of ACE-I produced by L. kefiri YK4 (IC(50) 0.261 mg/mL) and L. kefiri JK17 (IC(50) 0.308 mg/mL). Results of peptide identification showed that L. kefiri YK 4 could release as many as 1329, while L. kefiri JK 17 could release 174 peptides. The peptides produced were 95% derived from casein. The other peptides were from ά-lactalbumin, β-lactoglobulin, and serum amyloid A. The peptides produced consisted of 6-19 amino acid residues, with MWs of 634-2079 Dalton and detected at 317-1093 m/z. A total of 30 peptides have been recognized based on literature searches as ACE-I peptides (sequence similarity: 100%). CONCLUSION: L. kefiri YK4 and JK17 are the potential to be used as starter cultures to produce the bioactive peptide as ACE-I in fermented milk. |
format | Online Article Text |
id | pubmed-7096298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Veterinary World |
record_format | MEDLINE/PubMed |
spelling | pubmed-70962982020-04-01 Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria Rubak, Yuliana Tandi Nuraida, Lilis Iswantini, Dyah Prangdimurti, Endang Vet World Research Article BACKGROUND AND AIM: Fermented milk can be used to produce antihypertensive peptides. Lactic acid bacteria (LAB) with its proteolytic system hydrolyze milk protein during fermentation to produce several peptides, which include antihypertensive bioactive peptides. This study aimed to investigate the ability of indigenous LAB for the production of angiotensin-I-converting enzyme inhibitory (ACE-I) peptides in fermented milk and to characterize the ACEI peptides. MATERIALS AND METHODS: Reconstituted milk (11%) inoculated with ten LAB isolates, and then incubated at 37°C until it reaches pH 4.6. The evaluation was carried out for LAB count, lactic acid concentration, peptide content, and ACE-I activity. The low molecular weight (MW) peptides (<3 kDa) were identified using Nano LC Ultimate 3000 series system Tandem Q Exactive Plus Orbitrap high-resolution mass spectrometry. RESULTS: The result showed that the ten LAB isolates were able to produce ACE-I in fermented milk with the activities in the range of 22.78±2.55-57.36±5.40%. The activity of ACE-I above 50% produced by Lactobacillus delbrueckii BD7, Lactococcus lactis ssp. lactis BD17, and Lactobacillus kefiri YK4 and JK17, with the highest activity of ACE-I produced by L. kefiri YK4 (IC(50) 0.261 mg/mL) and L. kefiri JK17 (IC(50) 0.308 mg/mL). Results of peptide identification showed that L. kefiri YK 4 could release as many as 1329, while L. kefiri JK 17 could release 174 peptides. The peptides produced were 95% derived from casein. The other peptides were from ά-lactalbumin, β-lactoglobulin, and serum amyloid A. The peptides produced consisted of 6-19 amino acid residues, with MWs of 634-2079 Dalton and detected at 317-1093 m/z. A total of 30 peptides have been recognized based on literature searches as ACE-I peptides (sequence similarity: 100%). CONCLUSION: L. kefiri YK4 and JK17 are the potential to be used as starter cultures to produce the bioactive peptide as ACE-I in fermented milk. Veterinary World 2020-02 2020-02-21 /pmc/articles/PMC7096298/ /pubmed/32255978 http://dx.doi.org/10.14202/vetworld.2020.345-353 Text en Copyright: © Rubak, et al. http://creativecommons.org/licenses/by/4.0 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Rubak, Yuliana Tandi Nuraida, Lilis Iswantini, Dyah Prangdimurti, Endang Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria |
title | Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria |
title_full | Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria |
title_fullStr | Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria |
title_full_unstemmed | Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria |
title_short | Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria |
title_sort | angiotensin-i-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096298/ https://www.ncbi.nlm.nih.gov/pubmed/32255978 http://dx.doi.org/10.14202/vetworld.2020.345-353 |
work_keys_str_mv | AT rubakyulianatandi angiotensiniconvertingenzymeinhibitorypeptidesinmilkfermentedbyindigenouslacticacidbacteria AT nuraidalilis angiotensiniconvertingenzymeinhibitorypeptidesinmilkfermentedbyindigenouslacticacidbacteria AT iswantinidyah angiotensiniconvertingenzymeinhibitorypeptidesinmilkfermentedbyindigenouslacticacidbacteria AT prangdimurtiendang angiotensiniconvertingenzymeinhibitorypeptidesinmilkfermentedbyindigenouslacticacidbacteria |